Printer Friendly

Research and Markets: Haemophilus Influenzae Type B (Hib) Vaccine - Pipeline Assessment and Market Forecasts to 2019.

DUBLIN -- Dublin - Research and Markets (http://www.researchandmarkets.com/research/dr3tdz/haemophilus_influe) has announced the addition of GlobalData's new report "Haemophilus Influenzae Type B (Hib) Vaccine - Pipeline Assessment and Market Forecasts to 2019" to their offering.

GlobalData, the industry analysis specialist, has released its new report, Haemophilus Influenzae Type B (Hib) Vaccine - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Haemophilus influenzae type B vaccine Therapeutics market.

The report identifies the key trends shaping and driving the global Haemophilus influenzae type B vaccine Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Haemophilus influenzae type B vaccine Therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Haemophilus Influenzae Type b (Hib) Vaccine Market is Forecast to Show Low Growth up until 2019:

GlobalData's analysis shows that the global Haemophilus Influenzae Type b (Hib) vaccine market stood at $757.9m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 9.3% to reach $1,181.5m in 2011. GlobalData forecasts that the global Hib vaccine market will grow at a CAGR of 2.3% over the next eight years to reach $1,414.9m by 2019. Vaccination programs by the World Health Organization (WHO) have spurted the vaccination coverage rate rendering a high growth rate in the Hib vaccines market in the historical period from 2006 to 2011.

The Global Alliance for Vaccines and Immunization (GAVI) their Hib initiative (2005) promoted the use of Hib as a mandatory vaccine in national immunization programs in both developed and developing countries. The Hib vaccine market is expected to show low growth during the forecast period.

Companies Mentioned:

- Sanofi Pasteur

- GlaxoSmithKline

- LG Life Sciences Ltd

- Merck & Co., Inc.

- Novartis AG

For more information visit http://www.researchandmarkets.com/research/dr3tdz/haemophilus_influe

Source: GlobalData
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 10, 2012
Words:425
Previous Article:Research and Markets: North and South America Renewable Energy Policy Handbook 2012.
Next Article:Research and Markets: Wind Turbine Market, 2012 Update - Global Installations, Market Share and Key Country Analysis.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters